Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FITTER: Evolocumab for Non-Infarct Related Stenosis
NCT04141579Completed
- Sponsor
- Radboud University Medical Center
- Start
- Nov 2020
- Primary completion
- Nov 2023
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, double-blind trial of evolocumab in acute coronary syndrome (ACS) and coronary artery disease (CAD) (2 arms), sponsored by Radboud University Medical Center. Primary endpoints: Change in Fractional Flow Reserve at 12 weeks and Change in Lipid Core Burden Index at the 4mm maximal segment at 12 weeks. Started Nov 2020; status: completed.
02
Drugs
evolocumab
03
Conditions
acute coronary syndrome (ACS)coronary artery disease (CAD)
Beyond the preview
Go deeper on NCT04141579.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04141579.